(Q73396434)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

[Non-alcoholic steatohepatitis] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

non-alcoholic steatohepatitis

3 November 2019

main subject

1 reference

Juan Caballería

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Juan Rodés

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

670-675

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic steatohepatitis

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic Steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Prevalence of and risk factors for hepatic steatosis in Northern Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Association of nonalcoholic fatty liver disease with insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

An epilogue to jejunoileal bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Steatohepatitis: a tale of two "hits"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Cytokines in alcoholic and nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic steatohepatitis: An expanded clinical entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

The pathology of hepatic iron overload: a free radical--mediated process?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Hepatic iron and nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Hepatic steatosis: innocent bystander or guilty party?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Liver fibrosis in overweight patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Fasting in obesity: another cause of liver injury with alcoholic hyaline?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Metformin reverses fatty liver disease in obese, leptin-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Recurrence of nonalcoholic steatohepatitis following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973803-2

10.1016/S0025-7753(03)73803-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12747817%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference